Tempus, a Chicago, IL-based technology company advancing precision medicine through the collection and analysis of molecular and clinical data, secured an additional $110m in financing.
The round brought total funding to date to $320m and valued the company at $2 billion.
– Baillie Gifford,
– funds and accounts managed by T. Rowe Price,
– Revolution Growth,
– New Enterprise Associates (NEA) and
– other existing investors.
The company intends to use the additional funds to grow operations and expand into new therapeutic areas and geographies.
Led by Eric Lefkofsky, founder and CEO, Tempus is a technology company that is building a large library of molecular and clinical data and an operating system to make that data accessible and useful. It enables physicians to deliver personalized care for patients through an interactive analytical and machine learning platform, provides genomic sequencing services and analyzes molecular and therapeutic data to allow physicians and researchers to make real-time, data-driven decisions.
In three years, the company has built the most comprehensive data set in the industry, powered by clinical partners and collaborators across the country with the American Society of Clinical Oncologists (ASCO), academic medical centers and NCI designated cancer centers, hospital networks and community physicians across the United States.